Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Improvements in Patient-reported Migraine Pain Intensity and Composite Migraine Symptoms With Fremanezumab in the Real World
Headache
Headache Posters (7:00 AM-5:00 PM)
121

Fremanezumab, a fully-humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), has been approved for migraine prevention in adults with episodic migraine (EM) or chronic migraine (CM). However, little data exists on the effectiveness of fremanezumab in a real-world setting.

To evaluate real-world patient-reported changes in migraine pain intensity (MPI) and headache frequency/symptoms after fremanezumab treatment initiation.

In this retrospective, observational cohort study, data were extracted from September 2018 through June 2020 from the Midwest component of EMRClaims+®, an integrated health services database containing >20 million medical records from national commercial insurance claims, Medicare claims, and regional electronic medical records. Patients aged ≥18 years were administered fremanezumab, with enrollment or treatment history ≥6 months prior to initiating fremanezumab (index date) and enrollment or treatment encounter ≥1 month after the index date. MPI (10-point visual analog scale [VAS; 0=no pain, 10=worst pain]) and patient-reported change in headache frequency/symptoms were assessed pre-index and ≥1 month after fremanezumab initiation. Wilcoxon signed-rank tests were used to compare MPI and headache frequency/symptoms before and after fremanezumab initiation.

Overall, 74 patients (EM, n=21; CM, n=49) were eligible for analysis of MPI. MPI decreased significantly by 18% after fremanezumab initiation in the overall population: mean (standard deviation [SD]) VAS pain score was 5.47 (3.19) pre-index versus 4.51 (3.34) post-index (P=0.014). After fremanezumab initiation, pain levels decreased significantly by 45% in patients with EM (mean [SD] VAS pain score: pre-index, 5.57 [3.56]; post-index, 3.04 [3.37]; P=0.002) and decreased non-significantly by 10% in patients with CM after fremanezumab initiation (pre-index, 5.61 [2.99]; post-index, 5.06 [3.16]; P=0.203). In addition, 83.7% of patients who self-reported changes in headache frequency/symptoms reported improvement after fremanezumab initiation.

After fremanezumab initiation, MPI decreased significantly and the majority of patients reported an improvement in headache frequency/symptoms.

Authors/Disclosures
Alexander Mauskop, MD, FAAN (New York Headache Center)
PRESENTER
Dr. Mauskop has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Allergan. Dr. Mauskop has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Eli Lily. Dr. Mauskop has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Lundbeck. Dr. Mauskop has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biohaven. Dr. Mauskop has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. Mauskop has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Mauskop has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan.
Lois Lamerato (Henry Ford Health System) The institution of Lois Lamerato has received research support from Centers for Disease Control. The institution of Lois Lamerato has received research support from National Institutes of Health. The institution of Lois Lamerato has received research support from eMaxHealth. The institution of Lois Lamerato has received research support from Evidera. The institution of Lois Lamerato has received research support from AstraZeneca. The institution of Lois Lamerato has received research support from Policy Analysis, Inc. The institution of Lois Lamerato has received research support from Xcenda. The institution of Lois Lamerato has received research support from Pfizer.
Julian Casciano Julian Casciano has nothing to disclose.
Joshua *use 125685 Cohen (Teva Pharmaceuticals Industries) Joshua Cohen has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Stephen F. Thompson Stephen Thompson has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Lynda Krasenbaum Lynda Krasenbaum has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Zenobia Dotiwala ZENOBIA DOTIWALA has nothing to disclose.
Krishna Tangirala (Teva ;Pharmaceuticals) Krishna Tangirala has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Peter J. McAllister, MD, FAAN (New England Inst for Neurology and Headache) Dr. McAllister has received personal compensation for serving as an employee of Revance. Dr. McAllister has received personal compensation for serving as an employee of AbbVie. Dr. McAllister has received personal compensation for serving as an employee of Merz. Dr. McAllister has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aeon. Dr. McAllister has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for lilly. Dr. McAllister has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for teva. Dr. McAllister has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for abbvie. Dr. McAllister has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for biohaven. Dr. McAllister has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for lundbeck.